SEDA MEDI Inactive Instrument
SEDA MEDI Stock Nasdaq Stockholm
Equities
SE0009947534
Medical Equipment, Supplies & Distribution
| Sales 2024 * | 183M 16.77M 0 | Sales 2025 * | 244M 22.41M 0 | Capitalization | 1.88B 172M 0 |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | -12 -1.1 - | EV / Sales 2024 * | 10.2 x |
| Net cash position 2024 * | 23.8M 2.18M 0 | Net cash position 2025 * | - 0 - | EV / Sales 2025 * | 7.69 x |
| P/E ratio 2024 * |
-30.5
x | P/E ratio 2025 * |
-54.8
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on SEDA MEDI
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Johannes Doll
CEO | Chief Executive Officer | 43 | 21-09-30 |
Johan Spetz
DFI | Director of Finance/CFO | - | 22-04-03 |
Peter Fröberg
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hilde Furberg
BRD | Director/Board Member | 65 | 21-12-31 |
| Director/Board Member | 49 | 20-05-18 | |
Claus Bjerre
CHM | Chairman | 53 | 21-05-09 |
Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Companyâs main shareholders are board members, Linc AB and Magiola Consulting AB.
Calendar
2024-05-22
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -59.26% | 81.88M |
